Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease
Trial details
- Registry ID
- NCT05327803
- Drugs studied
- Epetraborole
TrialRedline tracks 2 clinical trials sponsored by AN2 Therapeutics, Inc: 1 Phase 2 / 3, 1 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study of Epetraborole in Patients With Treatment-refractory MAC Lung DiseaseNCT05327803 | Epetraborole | Terminated | 2024-12-18Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Phase 2 Study of Oral Epetraborole in Adults With Polycythemia VeraNCT07891533 | Epetraborole | Not yet recruiting | 2029-04Estimated |
Names as written in the registry records.
NCT05327803 · AN2 Therapeutics, Inc
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Phase 2: Assessment of Novel Patient Reported Outcome Instrument Psychometric Properties Measure: Phase 2: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole Measure: Phase 2: Percentage of Participants Achieving Clinical Response Measure: Phase 3: Percentage of Participants Achieving Clinical Response. After: Measure: Phase 2: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole Measure: Phase 2: Percentage of Participants Achieving Clinical Response Measure: Phase 3: Percentage of Participants Achieving Clinical Response.
NCT05327803 · AN2 Therapeutics, Inc
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Phase 2: Assessment of novel Patient Reported Outcome instrument psychometric properties Measure: Phase 2: Percentage of Participants Achieving Clinical Response Measure: Phase 2: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole Measure: Phase 3: Percentage of Participants Achieving Clinical Response. After: Measure: Phase 2: Assessment of Novel Patient Reported Outcome Instrument Psychometric Properties Measure: Phase 2: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole Measure: Phase 2: Percentage of Participants Achieving Clinical Response Measure: Phase 3: Percentage of Participants Achieving Clinical Response.